The London-based conversational AI provider has secured an initial seed investment to fund international expansion and product development.
"OpenDialog will finally enable businesses and consumers to realize the game-changing potential of conversational AI – moving beyond the often painful experiences delivered by current chatbots and AI assistants. The market has been crying out for a solution like this, one that not only drives real operational efficiencies but also enhances and joins up customer experience across a wide range of channels."
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
The grant will fund the rollout of gut-imaging technology to over 10 National Health Service trusts.
"One of the first questions we are asked is 'who else is using GIQuant?' and through this grant, we have an opportunity to really drive the tech into a lot of different types of hospitals and give the clinical community the time (and resource) to see how GIQuant can fit their workflows. This of course builds on regulatory clearance and a large number of published papers, but there is no substitution for hands-on use."
